Virus Clinical Trials

2 recruiting

Virus Trials at a Glance

337 actively recruiting trials for virus are listed on ClinicalTrialsFinder across 6 cities in 87 countries. The largest study group is Not Applicable with 67 trials, with the heaviest enrollment activity in Houston, Atlanta, and Philadelphia. Lead sponsors running virus studies include National Cancer Institute (NCI), National Institute of Allergy and Infectious Diseases (NIAID), and Takeda.

Treatments under study

About Virus Clinical Trials

Looking for clinical trials for Virus? There are currently 2 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new Virus trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about Virus clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 120 of 337 trials

Recruiting

Genetic Studies of Chronic Active Epstein-Barr Disease

Chronic Active Epstein-Barr Virus
National Institute of Allergy and Infectious Diseases (NIAID)300 enrolled1 locationNCT00032513
Recruiting
Phase 1

A Safety Assessment of Oral Letermovir in Infants With Symptomatic Congenital Cytomegalovirus

Congenital Cytomegalovirus Infection
National Institute of Allergy and Infectious Diseases (NIAID)12 enrolled10 locationsNCT06118515
Recruiting
Phase 2

Nivolumab in Epstein-Barr Virus (EBV)-Positive Lymphoproliferative Disorders and EBV-Positive Non-HodgkinLymphomas

LymphomaEpstein-Barr Virus InfectionsLymphoproliferative Disorder+1 more
National Cancer Institute (NCI)40 enrolled1 locationNCT03258567
Recruiting

In-depth Immunological Investigation of COVID-19.

Coronavirus Infections
Universitaire Ziekenhuizen KU Leuven100 enrolled1 locationNCT04327570
Recruiting
Phase 2

Phase II Trial of Neoadjuvant Chemotherapy (NAC) Alone or in Combination With Immunotherapy Vaccine PRGN-2009 in Subjects With Newly Diagnosed HPV-Associated Oropharyngeal (Head and Neck) Cancer

Squamous Cell Carcinoma of the Head and NeckDrug TherapyOropharynx+2 more
National Cancer Institute (NCI)70 enrolled1 locationNCT06223568
Recruiting
Phase 2

Phase II Study of Pacritinib in Kaposi Sarcoma Herpesvirus (KSHV)-Associated Multicentric Castleman Disease and KSHV-Associated Inflammatory Cytokine Syndrome (KICS)

KSHV Inflammatory Cytokine Syndrome (KICS)Kaposi Sarcoma Herpesvirus -Associated Multicentric Castleman Disease
National Cancer Institute (NCI)75 enrolled1 locationNCT06052618
Recruiting
Phase 2

Doravirine (DOR) in Human Immunodeficiency Virus (HIV)-Infected Children Aged 4 Weeks to <12 Years and <45 kg (MK-1439-066)

Human Immunodeficiency Virus (HIV) Infection
Merck Sharp & Dohme LLC84 enrolled24 locationsNCT04375800
Recruiting
Phase 2Phase 3

A Seamless Phase II/III, Observer-blind, to Evaluate Immunogenicity and Safety of Chikungunya Virus Vaccine in Healthy Subjects 12-65Years of Age.

Active Immunisation for Chikungunya Virus Infection
Bharat Biotech International Limited1,000 enrolled10 locationsNCT07555392
Recruiting
Phase 3

A Phase 3 Trial to Compare IV BCV Versus IV CDV for Treatment of Adenovirus Infection After Allo-HCT

Adenovirus Infections
SymBio Pharmaceuticals180 enrolled61 locationsNCT07387367
Recruiting
Phase 3

A Clinical Study of Molnupiravir to Prevent Severe Illness From Coronavirus Disease 2019 (COVID-19) in People Who Are High Risk (MK-4482-023)

Coronavirus Disease (COVID-19)
Merck Sharp & Dohme LLC3,082 enrolled222 locationsNCT06667700
Recruiting
Phase 2

A Study of Reduced Radiation Therapy and Standard-of-Care Chemotherapy in People With HPV-Positive Throat Cancer

Oropharyngeal CancerThroat CancerHuman Papilloma Virus+2 more
Memorial Sloan Kettering Cancer Center121 enrolled7 locationsNCT05491512
Recruiting
Phase 1

A Study of How Ibuzatrelvir is Taken up Into the Blood of Healthy Adults After Taking Different Tablets of Ibuzatrelvir

COVID-19 (Coronavirus Disease 2019)Coronavirus Disease 2019Coronavirus Disease 2019 (COVID-19)
Pfizer18 enrolled1 locationNCT07552779
Recruiting
Phase 2Phase 3

A Clinical Study of Islatravir and Ulonivirine for People With HIV-1 Who Have Not Been Treated Before (MK-8591B-062)

Human Immunodeficiency Virus Type 1 (HIV-1) Infection
Merck Sharp & Dohme LLC570 enrolled47 locationsNCT07266831
Recruiting
Phase 2

Neoadjuvant Chemotherapy and Programmed Cell Death Protein 1(PD-1) Inhibition for Head and Neck Cancer Treatment De-escalation (NeoScorch HN)

Head and Neck CancerLaryngeal CancerOral Cavity Cancer+6 more
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins75 enrolled1 locationNCT07209189
Recruiting

Harm Reduction in HIV Primary Care for PLWH Who Use Drugs

Substance UseHuman Immunodeficiency VirusStigma, Social
University of Pittsburgh768 enrolled3 locationsNCT05404750
Recruiting
Phase 3

A Study on the Immune Response and Safety of Vaccine Against Respiratory Syncytial Virus Given to Chinese Adults 18 to 59 Years of Age at Increased Risk of Respiratory Syncytial Virus Disease

Respiratory Syncytial Virus Infections
GlaxoSmithKline750 enrolled13 locationsNCT07220109
Recruiting
Phase 1

Lenacapavir Intensification to Disrupt HIV Reservoirs in Virologically Suppressed People With HIV Receiving Antiretroviral Therapy

Human Immunodeficiency Virus
National Institute of Allergy and Infectious Diseases (NIAID)50 enrolled1 locationNCT06819176
Recruiting
Not Applicable

Digital Telecytology for Triage of HPV-Positive Women in Cameroon

Human Papillomavirus InfectionCervical Cancer Screening MethodsCervical Intraepithelial Neoplasia Grade 2 (CIN2)
University Hospital, Geneva1,800 enrolled2 locationsNCT07550010
Recruiting
Phase 1

A Clinical Study of Letermovir (MK-8228) in Children and Adolescents Who Receive a Kidney Transplant (KT) (MK-8228-077)

Cytomegalovirus Prophylaxis
Merck Sharp & Dohme LLC40 enrolled12 locationsNCT07199465
Recruiting
Not Applicable

Study of Palivizumab in Children With High Risk of Severe Respiratory Syncytial Virus (RSV) Disease

Respiratory Syncytial Virus (RSV)
AstraZeneca138 enrolled2 locationsNCT06851806